eligibility_summary
Eligibility: Adults >=19 with measurable multiple myeloma, >=2 prior lines incl a proteasome inhibitor and lenalidomide, prior response then progression, ECOG 0-2, contraception/pregnancy testing as applicable. Key exclusions: prior mezigdomide or anti-BCMA, recent investigational therapy/surgery/radiation or SCT, EMD-only or CNS disease, infections, abnormal labs, grade >=2 neuropathy, interacting drugs (PPIs/strong CYP3A/PCABs), cardiac disease, HIV/HBV/HCV, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I/II single-arm trial in relapsed/refractory multiple myeloma testing: 1) Elranatamab: subcutaneous BCMA×CD3 bispecific T‑cell engager antibody. Mechanism: binds BCMA on malignant plasma cells and CD3 on T cells, redirecting T‑cell cytotoxicity and cytokine-mediated killing of myeloma cells. 2) Mezigdomide: oral CELMoD (cereblon E3 ligase modulator, next‑gen IMiD). Mechanism: binds cereblon to induce ubiquitination/degradation of IKZF1/IKZF3 (Ikaros/Aiolos), suppressing myeloma survival programs (e.g., IRF4/MYC) and enhancing T/NK activation and IL‑2 production. 3) Dexamethasone: glucocorticoid used mainly as premedication to reduce cytokine-related toxicity, also has anti‑myeloma effects. Targets/pathways: BCMA on plasma cells, CD3 on T cells, cereblon E3 ligase pathway with downstream Ikaros/Aiolos degradation and immune activation.